Weiying Gu

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial

Ming Shi, Jiaojiao Wang, Hongming Huang et al. · Nature Communications · 2024 · 104 citations · Full text

Medicine, Immunology, Oncology +16

Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial

Dian Zhou, Qian Sun, Jieyun Xia et al. · The Lancet Haematology · 2024 · 50 citations

Life Sciences, Hematology, Immunology +14

Value of the prognostic nutritional index (<scp>PNI</scp>) in patients with newly diagnosed, <scp>CD5</scp>‐positive diffuse large B‐cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group

Sha Ma, Bingpei Zhang, Tianyi Lu et al. · Cancer · 2022 · 36 citations

Agriculture, Hematology, Oncology +17

Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison

Linyan Cheng, Lujun Chen, Yuan Shi et al. · Molecular Cancer · 2024 · 36 citations · Full text

Life Sciences, Immunology, Oncology +17

High expression of &lt;em&gt;S100A8&lt;/em&gt; gene is associated with drug resistance to etoposide and poor prognosis in acute myeloid leukemia through influencing the apoptosis pathway

Shaoyan Hu, Xiaoyan Yang, Mingying Zhang et al. · OncoTargets and Therapy · 2016 · 31 citations · Full text

Life Sciences, Cancer Biology, Oncology +17